Clinical Trial: A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer

U.S., June 23 -- ClinicalTrials.gov registry received information related to the study (NCT07661173) titled 'A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer' on April 17.

Brief Summary: Exploring the efficacy and safety of adaptively adjusting treatment regimens based on ctDNA (MRD) status for EGFR mutation-positive NSCLC

Study Start Date: June 06

Study Type: INTERVENTIONAL

Condition: Non Small Cell Lung Cancer

Intervention: DRUG: Firmonertinib

80mg QD

DRUG: Firmonertinib/pemetrexed/Carboplatin

Drug: Firmonertinib daily and pemetrexed plus carboplatin on Day 1 of 21day cycles (every 3 weeks) for 4 cyc...